Boston Scientific cuts 2026 guidance for third time this year
Boston Scientific reported Q3 revenue of $5.14B, up 1.5% YoY, with net income of $582M. The company reduced its 2026 revenue growth forecast to 4.25% from 5.5%-6.5% and adjusted EPS guidance to $3.16-$3.18. Challenges in Watchman and electrophysiology businesses, along with a cyberattack, impacted performance. The stock fell 7% to $42.02. The $14.5B Penumbra acquisition is now expected to close in early 2027.
How this was made
The 30-second read
Why it matters
The guidance reduction and operational disruption create immediate downside risk, but the delayed acquisition may free cash flow later.
Market read
First report of guidance cut and cyberattack loss; traders can act on the negative outlook.
What to watch
Potential cost‑saving measures and upcoming product launches could mitigate the revenue decline.
Background
Boston Scientific disclosed Q3 results, a cyberattack loss, and delayed closing of its $14.5B Penumbra acquisition.
Ticker impact
Boston Scientific cut its 2026 revenue and EPS guidance and reported a $150M cyberattack hit, driving the stock down ~7% at open.
likely further decline as investors price in weaker outlook and cyber risk
The article provides the first disclosure of the guidance reduction and quantifies the cyberattack hit, both material to valuation.
Market effects
MedTech sector may face broader scrutiny as other device makers confront cyber risk and slower growth in electrophysiology.
U.S. healthcare stocks could see modest pullback in early trading.
Limited to U.S. markets; no immediate global ripple beyond investors tracking large‑cap medtech.
Counterpoint
The guidance cut may be overblown if the cyberattack impact is one‑off and the underlying product pipeline remains strong.
Key entities
- companyBoston Scientific
Medical device maker reporting guidance cut and cyberattack impact.
- companyPenumbra
Target of Boston Scientific's $14.5B acquisition, closing delayed to early 2027.
